Scholars@Duke
Tatyana Der

Tatyana Der

Assistant Professor of Medicine
Medicine, Hospital Medicine
tatyana.der@duke.edu
Duke Raleigh Hospital, Raleigh, NC 27609
3400 Wake Forest Rd, Raleigh, NC 27609

Selected Publications

Characterizing Intervention Components and Complexity of Nonpharmacologic Healthcare Interventions to Manage Distress Behaviors in Older Adults.

Journal Article J Appl Gerontol · January 2026 Distress behaviors are common in residential care settings and contribute to staff burnout and poor quality of life for older adults. While nonpharmacologic interventions reduce distress behaviors, implementation in routine care remains challenging. Our st ... Full text Link to item Cite

An Evidence Map of the Women Veterans' Health Literature, 2016 to 2023: A Systematic Review.

Journal Article JAMA Netw Open · April 1, 2025 IMPORTANCE: Women veterans are the fastest-growing veteran subpopulation in the US. Women veterans often experience military service-related health issues in addition to conditions common to all women. Because women veterans are more likely to receive care ... Full text Link to item Cite

Effectiveness of Synchronous Postdischarge Contacts on Health Care Use and Patient Satisfaction : A Systematic Review and Meta-analysis.

Journal Article Ann Intern Med · February 2025 BACKGROUND: Postdischarge contacts (PDCs) after hospitalization are common practice, but their effectiveness in reducing use of acute care after discharge remains unclear. PURPOSE: To assess the effects of PDC on 30-day emergency department (ED) visits, 30 ... Full text Open Access Link to item Cite

Resource Use in the Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM): A Secondary Data Analysis.

Journal Article CHEST Crit Care · December 2024 BACKGROUND: Coronavirus disease 2019 (COVID-19) pneumonia requires considerable healthcare resources. RESEARCH OBJECTIVE: Examine if a single dose of infliximab or abatacept, in addition to remdesivir and steroids, decreased resource utilization among part ... Full text Link to item Cite

Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.

Journal Article Clin Infect Dis · June 14, 2024 BACKGROUND: Persistent mortality in adults hospitalized due to acute COVID-19 justifies pursuit of disease mechanisms and potential therapies. The aim was to evaluate which virus and host response factors were associated with mortality risk among participa ... Full text Link to item Cite

Health Care Team Interventions to Reduce Distress Behaviors in Older Adults: A Systematic Review.

Journal Article Clin Gerontol · 2024 OBJECTIVES: This review examines health care team-focused interventions on managing persistent or recurrent distress behaviors among older adults in long-term residential or inpatient health care settings. METHODS: We searched interventions addressing heal ... Full text Link to item Cite

543. Sex Differences in Clinical Presentation and Outcomes of Adults Hospitalized with COVID-19 Pneumonia After Administration of Infliximab, Abatacept or Cenicriviroc: Subgroup Analysis from the ACTIV-1 Master Protocol

Journal Article Open Forum Infectious Diseases · November 27, 2023 AbstractBackgroundA growing body of evidence suggests potential sex differences in the clinical outcomes of COVID-19. In this study we ... Full text Cite

Abstract 14153: P2Y12 Inhibitors and Quality of Life Outcomes in Critically Ill Patients Hospitalized for COVID-19: A Pre-Specified Secondary Analysis of the ACTIV4a Randomized Clinical Trial

Journal Article Circulation · November 7, 2023 Background: Post-acute sequela of COVID-19 (PASC) is a complication of SARS-CoV-2 causing persistent symptoms and impaired functional status. We studied the effect of P2Y12 inhibitors on health-relate ... Full text Cite

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.

Journal Article JAMA · July 25, 2023 IMPORTANCE: Immune dysregulation contributes to poorer outcomes in COVID-19. OBJECTIVE: To investigate whether abatacept, cenicriviroc, or infliximab provides benefit when added to standard care for COVID-19 pneumonia. DESIGN, SETTING, AND PARTICIPANTS: Ra ... Full text Open Access Link to item Cite

Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.

Journal Article Ann Intern Med · April 2023 BACKGROUND: Patients hospitalized with COVID-19 have an increased incidence of thromboembolism. The role of extended thromboprophylaxis after hospital discharge is unclear. OBJECTIVE: To determine whether anticoagulation is superior to placebo in reducing ... Full text Link to item Cite

Impact of the COVID-19 pandemic on adult mental health-related admissions at a large university health system in North Carolina - one year into the pandemic.

Journal Article PLoS One · 2023 OBJECTIVE: Pandemic-associated stress may have exacerbated preexisting mental health and substance use disorders (MH/SUD) and caused new MH/SUD diagnoses which would be expected to lead to an increase in visits to emergency departments and hospital admissi ... Full text Open Access Link to item Cite

Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19.

Journal Article medRxiv · September 26, 2022 BACKGROUND: We investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19. METHODS: We conducted a master protocol to investigate immunomodulators ... Full text Link to item Cite

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.

Journal Article Lancet Infect Dis · May 2022 BACKGROUND: We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereaf ... Full text Link to item Cite

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.

Journal Article Ann Intern Med · February 2022 BACKGROUND: In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futilit ... Full text Link to item Cite

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.

Journal Article N Engl J Med · March 11, 2021 BACKGROUND: LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on ... Full text Link to item Cite

Vitamin D and prostate cancer survival in veterans.

Journal Article Mil Med · January 2014 Prostate cancer remains the second most commonly diagnosed cancer among the male population worldwide. Vitamin D deficiency has been linked to prostate cancer and its aggressiveness. Herein, we initiated a retrospective study to evaluate vitamin D status a ... Full text Link to item Cite

HIF-1α in heart: protective mechanisms.

Journal Article Am J Physiol Heart Circ Physiol · September 15, 2013 Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor that directs many of the cellular responses to hypoxia. In these studies, we have used a mouse model containing a cardiac-specific, oxygen-stabilized, doxycycline (Dox)-off regulated HIF-1α tra ... Full text Link to item Cite